Consistent progression-free survival (PFS) benefit observed across all of the following prespecified patient subgroups regardless of treatment history or baseline characteristics1
35% risk reduction in patients with renal impairment and 53% risk reduction in patients with poor cytogenetic risk1,2
- San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206.
- FARYDAK® (panobinostat). EU Summary of Product Characteristics. Novartis AG; April 2016.